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Available online 15 June 2016A novel Schiff base [C20H23NO3], has been prepared and characterized using FT-IR, UV–vis, 1H NMR spectroscopy,
elemental analysis and X-ray crystallography. A copper (II) complex [Cu(C20H22NO3)2]·H2O has also been syn-
thesized and characterized. The new ligand and complex thus obtained were investigated by their interaction
with calf thymus DNA and BSA using electronic absorption spectroscopy, ﬂuorescence spectroscopy, and thermal
denaturation. The intrinsic binding constants Kb of the ligand and Cu (II) complex, with CT-DNA obtained from
UV–vis absorption studies were 1.53 × 104 M−1 and 3.71 × 105 M−1, respectively. Moreover the addition of
the two compounds to CT-DNA (1:2) led to an increase of the melting temperature of DNA up to around 2.61 °C
for the ligand and 3.99 °C for the Cu (II) complex. The ligand and Cu (II) complex bind to CT-DNA via a partial
intercalative, as shown by the experimental data. In addition, the albumin interactions of the two compounds
were studied by ﬂuorescence quenching spectra, the results indicating that the binding mechanism is a static
quenching process. The in vitro cytotoxicity of the two compounds on three different cancer cell lines was eval-
uated by MTT assay. The results showed that the copper complex exerted enhanced cytotoxicity compared with
the Schiff base ligand; thereby, this complex clearly implies a positive synergistic effect. Furthermore, the copper
complex showed a high, selective, and dose-dependent cytotoxicity against cancer cell lines.





Interaction with DNA and BSA
Cytotoxic activity1. Introduction
Gabapentin, 1-(aminomethyl) cyclohexaneacetic acid, Neuronti
(Gpn) structurally belongs to the neurotransmitter gamma-
aminobutyric acid (GABA), widely studied for its signiﬁcant inhibitory
action in the central nervous system [1]. Gpn has been applied in the
treatment of neuropathic pain. It is a new generation antiepileptic
used as add-on therapy and monotherapy in patients with partial sei-
zures [2]. A safe and effective seizure is a concern for an increasing num-
ber of adults suffering from epilepsy. Epilepsy also imposes a
remarkable economic load on society [3]. The selection of an antiepilep-
tic drug depends on how it functions with regard to the speciﬁc seizure
type, tolerability, and safety. Furthermore, gabapentin can be consid-
ered as an emergent solution for the “pain riddle”. Starting from this
point, more randomized, double blind studies, which compare analgesic
drugs with gabapentin, may be relevant to identifying the ﬁrst choice
therapy for acute and chronic pain relief [4]. Thus, the search for novel
chemical entities for the cure of epilepsy is essential [5,6]. Usually. This is an open access article underformed by condensation of a primary amine with an active carbonyl
compound, Schiff bases are compounds containing the azomethine
group (R\\C_N). The biological activities and decreased cytotoxicity
of both metal ion and Schiff base ligand are due to the attachment of
transition metals in to these compounds [7–9]. Considering their great
ﬂexibility and various structural aspects, a wide range of transition
metal complexes of Schiff base ligands have been synthesized and
the structure function relationships of the resulting complexes
have been extensively focused on in recent years [10–14]. Piotr et al.
have synthesized various compounds such as amino thiazoles, 2-hydroxy-
1-napthalaniline, amino sugars, aromatic aldehydes, ketones,
thiosemicarbazides, amino acids, pyrazolone, etc. [15]. Recently, some
novel coordination compounds based on Schiff base ligands were
found useful as potential pro drugs. Consequently, transition metal
complexes of Schiff bases have been extensively studied as promising
alternatives to traditional cisplatin for anticancer drugs. In addition,
Schiff base complexes have attractedmuch attention given their impor-
tant role in the improvement of novel therapeutic agents and novel
nucleic acid structural probes [16]. DNA is an essential cellular receptor
and is the primary target molecule for most anticancer and antiviral
therapies. Many compounds apply their anticancer effects via bindingthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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the tumor cells, which is the basis for designing new, more effective an-
ticancer drugs, the efﬁcacy ofwhichdepends on themode and tendency
of the binding [17]. Revealing the features leading to increased DNA
binding capability by small ligands or metal complexes is important
for designing efﬁcient chemotherapeutic agents and better DNA
targeted anticancer drugs [18]. Therefore, the DNA-binding studies of
small metal complexes are very signiﬁcant in the improvement of
new anticancer drugs [19,20]. Moreover, naphthaldehyde Schiff base li-
gand, an aromatic planar ligandwith carbonyl O andNdonor atoms, can
coordinate tometal ions to formmetal intercalators, which show strong
intercalation with DNA. The selection of a metal ion is the most signiﬁ-
cant factor in the design of a metal based chemotherapeutic agent [21].
Copper is a crucial cofactor in tumor angiogenesis processes and is a bio-
essential and bio-relevant element, which is an inseparable component
of many enzymes, including superoxide dismutase, tyrosinase, cerulo-
plasmin, etc. [22,23]. Many copper (II) complexes with biological activ-
ities such as antibacterial, anti-cancer and cancer inhibiting properties
have already been dealt with in the literature [24,25]. Palaniandavar
and co-workers have reported that copper (II) complexes are the best
alternatives to cisplatin because copper plays many signiﬁcant parts in
biological systems and is a biocompatible metal [26], considering the
strong interactions of copper complexes with DNA through surface as-
sociations or intercalation [27]. Moreover, the investigation of the inter-
actions of novel copper (II) Schiff base complexes with DNA is greatly
important for disease defense, new medicine design and clinical appli-
cation of drugs [28]. A copper complex has been synthesized from
gabapentin drug Schiff base and the corresponding biological properties
such as DNA binding, protein binding, and in vitro cytotoxicity have
been studied. One of the important properties of a drug is its protein
binding degree, affecting its effective solubility, biodistribution, and
half life in the body [29]. Biomolecule proteins play an important role
in transportation and deposition of endogenous and exogenous sub-
stances including fatty acids, hormones, and drugs. They also have
many physiological functions. BSA, bovine serum albumin, is often se-
lected as a target protein to study interactions with small molecules
due to its low cost, ready accessibility and similarity to human serumal-
bumin [30]. A stable protein drug complexwith a dominant role in stor-
age and drug disposition may be formed by a signiﬁcant interaction of
any drugwith a protein. Therefore, understanding themechanismof in-
teraction of a bioactive compound with BSA, a well studied protein, is
important [31]. A new Schiff base derived from the gabapentin drug
and copper complex has been studied in this work from four aspects;
(i) synthesis and characterization of the ligand and complex using spec-
troscopy and X-ray diffraction, (ii) study of the ability of the two com-
pounds to interact with DNA and the interaction mechanism using
UV–vis, ﬂuorescence spectroscopy, and thermal denaturation, (iii)
monitoring of the protein binding ability by UV absorption and trypto-
phan ﬂuorescence quenching experiment in the presence of the two
compounds using BSA as a model protein, and (iv) a comparative
study of the in vitro cytotoxicity of the three compounds on three
human carcinomas (JURKAT, SKOV3, and U87) and peripheral blood
mononuclear cell (PBMC) by MTT assay.
2. Experimental
2.1. Materials
All chemicals and solvents used for synthesis were commercially
available, reagent grade andwere usedwithout further puriﬁcation. Sol-
vents and starting materials were supplied by Sigma Aldrich or Alfa
Aesar Chemical Companies and used without further puriﬁcation. BSA
and Calf thymus DNA (CT-DNA) were purchased from Sigma Aldrich
Chemical Company and were used as supplied. The DNA concentration
per nucleotide was determined by absorption spectroscopy using the
molar absorption coefﬁcient (ε = 6600 M−1 cm−1 at 260 nm) [32].The stock solutions were stored at 5 °C and used over a period of
4 days. All the experiments involving interactions of the compounds
with DNA were performed using doubly distilled water buffer contain-
ing 5 Mm Tris–HCl [tris (hydroxymethyl)-aminomethane] and 50 mM
NaCl, adjusted to pH 7.4 using hydrochloric acid. Ligand and Cu complex
stock solutions were prepared by dissolving the two compounds in
water and DMSO as the co-solvent, and then diluted with the corre-
sponding buffer to the necessary concentrations for all the experiments.
The ﬁnal DMSO concentration did not exceed 0.5% v/v. JURKAT (human
leukemic T cell line), SKOV3 (human ovarian cancer cell line), U87
(human glioblastoma cell line), and PBMC (peripheral blood mononu-
clear cell) were supplied by the National Cell Bank of Pasteur Institute,
Tehran, Iran. Cells were cultured in Dulbecco's Modiﬁed Eagle Medium
(DMEM) supplemented with 10% heat inactivated fetal bovine serum
(FBS), 100 U ml−1 penicillin, 100 μg ml−1 streptomycin and 5 mM L-
glutamine. The cell lines were subsequently grown at 37 °C in a humid-
iﬁed atmosphere containing 5% CO2. All reagents and cell culture media
were purchased from Gibco Company (Germany).
2.2. Physical Measurements
Fourier transform infrared (FT-IR) spectra were recorded as KBr
disks on an FT-IR JASCO-680 spectrophotometer in the 4000–
400 cm−1 ranges using the KBr pellets technique. The elemental analy-
ses were performed on a Leco, CHNS-932 apparatus. UV–vis spectra
were recorded on a JASCO V-570 spectrophotometer in the 190–
900 nm range. NMR spectra were measured on a Bruker spectrometer
at 400.13 MHz. The Tm spectra were recorded on a Varian BioCary-100
UV–vis spectrophotometer using a 1 cm path length cell. Solutions
were prepared by dissolving the complex in water buffer containing
5 mM Tris–HCl (pH 7.4) and 50 mM NaCl. Electrospray mass spectra
were obtained using a Shimadzu LCMS-2010 EV liquid chromatography
mass spectrometer.
2.3. Synthesis of the Schiff Base Ligand
The Schiff base ligand, was prepared by equimolar (1:1 mol ratio)
condensation between gabapentin (0.160 g, 1 mmol) and 2-hydroxy1-
naphthaldehyde (0.172 g, 1 mmol) by stirring for 3 h at room tempera-
ture in absolute ethanol and recrystallization using absolute methanol
by slow evaporation. Ligand yield (86%) (0.75 mg); color: yellow; MP:
215 °C; anal., calc. for, [C20H23NO3]; C, 73.82; H, 7.12; N, 4.30; O,
14.75%. Found; C, 73.50; H, 7.24; N, 4.35; O, 14.90%. FT-IR (KBr,
cm−1): 3436 ν (O\\H), 2929 and 2855 ν (C\\H), 1690 νas (COO–),
1638 ν (C_N), 1545 ν (C_C), 1359 νs (COO–) 0.1030 ν (C\\O), 964 ν
(C\\N)·1H NMR (CDCl3, δ, ppm): 8.43 (s, 1H, HC_N), 7.65–7.67 (d,
1Ha, Ar\\H, 3J = 8.3), 7.53–7.55 (d, 1Hb, Ar\\H, 3J = 7.1), 7.47–7.49
(d, 1Hc, Ar\\H, 3J= 9.2), 7.29–7.32 (t, 1Hd, Ar\\H 3J= 7.5), 7.10–7.14
(t, 1He, Ar\\H 3J= 7.4) 6.76–6.79 (d, 1Hf, Ar\\H, 3J= 9.2) 3.50 (s, 2H,
CH2), 2.30 (s, 2H CH2), 1.39–1.78 (m, 10H, cyclohexyl methylenes
group). UV–vis (solvent methanol λmax, nm (ε, M−1 cm−1)): 232
(1.82 × 104), 310 (4.50 × 103), 394 (5.68 × 103).
2.4. Synthesis of [Cu(C20H22NO3)2]·H2O
The synthesis of copper complex is as follows: copper (II) acetate
tetrahydrate (0.249 g, 1.0 mmol) and ligand (0.620 g, 2.0 mmol) were
added to a 40 mL methanolic solution and stirred for 5 h. The formed
Cu (II) complex was ﬁltered and washed with diethyl ether.
Copper (II) complex [Cu(C20H22NO3)2]·H2O, yield (90%), color: light
green; MP: 365 °C; anal., calc. for C40H46CuN2O7: C, 65.78; H, 6.35; N,
3.84; O, 13.48%. Found; C, 65.22; H, 6.53; N, 3.77%; O, 13.36%. FT-IR
(KBr, cm−1) 3382 ν (O\\H), 2924 and 2856 ν (C\\H), 1600 ν (C_N),
1549 νas (COO), 1509 ν (C_C), 1310 νs (COO), 1048 ν (C\\OH), 961 ν
(C\\N),458 ν (Cu\\N) and 541 ν (Cu\\O). UV–vis (solvent methanol
Scheme 1. Synthesis of the copper (II) complex.
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3. Results and Discussion
3.1. Synthesis and Spectroscopic Characterization
In this study, 2-hydroxy-1-naphtaldehyde was used to react with
gabapentin and a novel Schiff base was synthesized from the
gabapentin drug. In addition, copper (II) complex is obtained in one
step by the reaction of [Cu (OAc)2]·4H2O with ligand in MeOH under
stirring for 5 h (Scheme 1). The compound was characterized by FT-IR
spectroscopy, elemental analysis (C, H, N), and UV–vis spectral studies.
The ESI–MS studies conﬁrmed the formula proposed for the copper
complex.
3.1.1. Infrared Spectra
The FT-IR spectra of the Schiff base ligand and copper (II) complex
exhibit several bands in the 400–4000 cm−1 region (Sections 2.3–2.4).
The azomethine vibration of the Schiff base ligand appeared at
1639 cm−1. Because of bond formation between the metal and the
imine nitrogen, the C_N bond stretchingwas shifted to lower frequen-
cies relative to the free Schiff base and appeared at 1600 cm−1 for the
copper complex [33]. The Δν= [νas(CO2)− νs(CO2)] value was used
to determine the nature of binding of carboxylate to a transition metal
ion. In general, the difference inΔν between asymmetric and symmetric
νs(CO2) absorption frequencies below 200 cm−1 suggests the bidentate
carboxylate moiety while absorption frequencies N200 cm−1 implicate
unidentate carboxylation. In the copper complex, the Δν values wereFig 1. The labeled ORTEP diagram of Schiff base liganabove 239 cm−1 suggestive of coordination of the carboxylate group
in a monodendate fashion [34]. In the Cu (II) complex, these can be
assigned to the ligand coordinated to the metal ion via imine nitrogen,
phenolic oxygen and oxygen carboxylic acid atoms. Moreover, the for-
mation of a copper complex was also revealed by the presence of medi-
um intensity ν (M–N) and ν (M–O) bands at about 458 and 541 cm−1,
respectively, in the far IR region [35].
3.1.2. Electronic Absorption Spectra
The UV–vis spectral data (300–800 nm) of the ligand and synthe-
sized complex are shown in Sections 2.3–2.4. The Schiff base ligand ex-
hibits electronic transitions with a strong band at 232 nm, assigned to
π–π* transitions [36]. The transition at 310 nm is assigned to the π–π*
type and the band at 394 nm involves π–π* transition related to the
azomethine group. The band at 394 nm was shifted to lower wave-
lengths and appeared at about 376 nmmixedwith charge transfer tran-
sition. In addition, the bands around 376 nm are assigned to metal-to-
ligand charge transfer (MLCT) transitions [37]. The spectral similarity
suggests that all the complexes present the same chromophore in solu-
tion. The complex revealed d–d transitions in the lower frequency re-
gion centered at 678 nm and a band in UV region at 240 nm
consistent with their octahedral geometry, respectively. Moreover, the
distorted octahedral Cu (II) complex displays one band at 678 nm, cor-
responding to 2Eg→ 2T2g (2B1g→ 2Eg)) transition [38].
3.1.3. Mass Spectroscopy
The formation of copper complex and the speciation of various ionic
forms in DMSO/MeOH solution were studied with ESI–MS. The spectra
of the complex displayed prominent peaks corresponding to thed. Thermal ellipsoids are at 30% probability level.
Fig 2. Packing diagram of ligand showing hydrogen bonds.
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complex showed a peak at m/z+ 713.45 corresponding to the
[C40H44CuN2O6 + 2H] fragment. The molecular formulae assigned to
these complexes are further supported by ESI-mass studies.
3.1.4. Crystal Structure of the Ligand
3.1.4.1. Crystal Structure Determination and Reﬁnement. Crystals of a
Schiff base ligand suitable for X-ray crystallography were obtained
from methanol solution at room temperature. The X-ray diffraction
measurements were made on a STOE IPDS-2 T diffract meter with
graphite monochromated Mo-Kα radiation. For the Schiff base ligand,
a yellow needle shaped crystal was chosen using a polarizing micro-
scope and wasmounted on a glass ﬁber whichwas used for data collec-
tion. Cell constants and orientation matrices for data collection were
obtained by least-squares reﬁnement of diffraction data from 4458
unique reﬂections. Data were collected to a maximum 2θ value of
58.36° in a series of ω scans in 1° oscillations and integrated using the
Stoe X-AREA [39] software package. The datawere corrected for Lorentz
and Polarizing effects. The structures were solved by direct methods
[40] and subsequent difference Fourier maps and then reﬁned on F2
by a full-matrix least-squares procedure using anisotropic displacement
parameters [41]. The atomic factors were taken from the International
Tables for X-ray Crystallography [42]. All reﬁnements were performed
using the X-STEP32 crystallographic software package [43]. The ORTEP
diagram of the molecular structure of the ligand is shown in Fig. 1. De-
tails of the crystal structure analysis and reﬁnement for the ligand are
reported in Table 1. Fig. 2, Table 2 and Table 3 show selected bond
length, angles and the summary of hydrogen bond parameter,
respectively.
4. DNA Binding Studies
4.1. Electronic Absorption Titration
Measurement of the effects of the free ligand and the Cu (II) complex
with CT-DNAwas used to study their binding ability by electronic spec-
troscopy. Compounds binding with DNA usually show hypochromismTable 1
Crystallographic and structure reﬁnement data for ligand.
Empirical formula C20H23NO3
Formula weight 325.39




Crystal size (mm3) 0.35 × 0.15 × 0.05
a (Å) 9.1539 (18)
b (Å) 9.7260 (19)
c (Å) 9.890 (2)
α (°) 89.59 (3)
β (°) 83.21 (3)
γ (°) 71.98 (3)
Volume (Å3) 831.1 (3)
Z 2
Densitycalc (g cm−1) 1.300
θ ranges for data collection (°) 2.36–29.18
F (000) 348
Index ranges −12 ≤ h ≤ 12
−13 ≤ k ≤ 13
−13 ≤ l ≤ 13
Data collected 9195
Unique data, (Rint) 4458, (0.1207)
Parameters/restrains 225/0
Final R1/wR2a (I N 2σ(I) ) 0.0871/0.1633
Final R1/wR2a (all data) 0.1658/0.1958
Goodness-of-ﬁt on F2 (S) 1.088
Largest diff. peak and hole (e Å−3) 0.279,−0.294
a R1 = Σ||Fo|− |Fc||/Σ|Fo|, wR2 = [Σ(w(Fo2− Fc2)2) / Σw(Fo2)2]1 / 2.and bathochromism [44]. The corresponding Tris–HCl buffer solution
was the reference solution. Equal amounts of DNA were added to both
the compound and reference solutions to eliminate the absorbance of
DNA while measuring the absorption spectra. The solution obtained
by adding DNA to the compounds in Tris–HCl buffer was allowed to
equilibrate at room temperature for 5 min and then scanned in the
range of 200–600 nm [45,46].
An effective method for the examination of the binding modes of
metal complexes with DNA is electronic absorption spectroscopy. In
general, hypochromism and a red shift are associated with the binding
of metal complexes to DNA, because of the intercalativemode involving
a strong stacking interaction between the aromatic chromophore of the
complexes and the base pairs of DNA. UV spectroscopy was used to
study the potential CT-DNA binding ability of a complex by following
the intensity changes of the intraligand π–π* transition band at 232
and 310 nm [47]. The absorption spectra of the ligand and its Cu (II)
complex in the absence and presence of CT-DNA are shown in Fig. 3.
As shown in the ﬁgure, the binding of the ligand to duplex DNA de-
creases the absorption intensities with signiﬁcant hypochromisms of
about 28.17, 29.02 and 29.4% at 232, 310 and 394 nm, respectively.
Meanwhile, the Cu (II) complex absorption bands exhibited
hypochromisms of about 54.12% at 240 nm, 40.67 and 35% with partial
red shifts of 2 and 1 nm at 310 and 376 nm, respectively, and only a
small shift in the 2 nm wavelength. This observation is attributed to a
partial intercalative binding [48]. The binding constants (Kb) of L and
the complex to CT DNAwere determined bymonitoring the absorbance
changes at 232 (for L) and 240 nm (for the Cu (II) complex) withTable 2
Selected bond distances (Å) and bond angles (degrees) for ligand.
O(1)\\C(9) 1.287 (4) C(11)\\N(1)\\C(12) 124.4 (2)
O(2)\\C(15) 1.213 (4) C(15)\\C(14)\\C(13) 115.4 (2)
O(3)\\C(15) 1.312 (4) O(2)\\C(15)\\O(3) 123.5 (3)
O(3)\\H(3A) 1.00 (4) O(3)\\C(15)\\C(14) 113.2 (2)
N(1)\\C(11) 1.302 (4) C(17)\\C(16)\\C(13) 114.1 (2)
N(1)\\C(12) 1.457 (4) N(1)\\C(12)\\C(13) 112.8 (2)
C(14)\\C(15) 1.508 (4) O(1)\\C(9)\\C(10) 121.4 (3)
C(19)\\C(20) 1.532 (5) O(1)\\C(9)\\C(8) 120.9 (3)
Table 3
Hydrogen bond geometric parameters (Y− A⋯H− D) for liganda.
D\\H⋯A D\\H/Å A⋯H/Å A⋯D/Å A⋯H\\D/deg
N(1)\\H(1A)⋯O(1) 0.93 (4) 1.83 (4) 2.579 (3) 135 (3)
O(3)\\H(3A)⋯O(1)#1 1.00 (4) 1.58 (5) 2.563 (3) 168 (4)
C(12)\\H(12A)⋯O(2) 0.9900 2.5600 3.185 (4) 121.00
C(12)\\H(12A)⋯O(2)#2 0.9900 2.5300 3.444 (4) 153.00
C(16)\\H(16B)⋯N(1) 0.9900 2.5600 2.952 (4) 104.00
a Symmetry codes: #1: 1 + x,y,z; #2: 2− x,−y,−z.
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afﬁnity of the ligand and complex towards DNA. The data were then
ﬁt into the following equation and the intrinsic binding constant, Kb,






Kb εb−ε fð Þ
ð1Þ
where [DNA] is the concentration of DNA in base pairs and the apparent
absorption coefﬁcient, εa, corresponds to Aobs/[compound], εf refers to
the extinction coefﬁcient of the free compound and εb is the extinction
coefﬁcient of the compound when fully bound to DNA. The plot of
[DNA] / (εa− εf ) vs. [DNA] (Fig. 3) gave a slope and intercept equal to
1 / (εb − εf) and 1 / Kb(εb − εf), respectively. Kb is the ratio of the
slope to the intercept. The observed values of Kb also indicate that the
ligand and the Cu (II) complex bind to DNA via a partial intercalative
mode [50,51]. The magnitudes of the intrinsic binding constants (Kb)
were calculated to be 1.53 × 104 and 3.71 × 105 M−1 for the ligand
and the Cu complex, respectively. The calculated values of Kb also
show that the ligand and the Cu (II) complex bind to DNA via a partialFig 3. Absorption spectra of ligand (A), and complex (B) in buffer solution (5 mM
Tris–HCl/50 mM NaCl at pH 7.4) upon addition of CT DNA. [Ligand] = 4 × 10−5 mol L−1,
[DNA] = 0–3.1 × 10−5 mol L−1. [Complex] = 8 × 10−4 mol L−1, [DNA] = 0–
2.1 × 10−5 mol L−1. Arrow shows that the absorption intensities decrease upon increasing
DNA concentration. Inset: plots of [DNA] / [ea− ef] vs. [DNA] for the titration of 1a and 1b
with CT-DNA.intercalative mode. The complex showed more hypochromicity than
the ligand, indicating that the binding strength of the Cu (II) complex
is stronger than that of the free ligand. Though it has been found that
the compounds can bind to DNAby intercalation from the electronic ab-
sorption studies, the binding mode needs to be proved through some
more experiments.
From the values of the binding constant (Kb), free energy (ΔG) of the
compound–DNA complex was calculated using Eq. (2):
ΔG ¼−RT lnKb ð2Þ
Binding constants are a measure of the compound–DNA complex
stability while the free energy indicates the spontaneity/non-spontane-
ity of compound–DNA binding. Free energies of ligand and Cu complex
were evaluated as negative values (−5.21 and−6.04 kJ mol−1), show-
ing the spontaneity of compound–DNA interaction. However, these re-
sults indicate that the Cu complex binds to DNA more spontaneously
compared to the ligand.
4.2. Fluorescence Studies of Competitive Interaction of the Compounds with
MB-Ds-DNA
No emission bandwas observed in theﬂuorescencemeasurement of
the ligand and copper (II) complex with or without CT-DNA at ambient
temperature in aqueous solutions. Therefore, the binding of compounds
with CT-DNA cannot be directly shown in the emission spectra. To fur-
ther investigate the interaction mode of the ligand and complex with
DNA, the competitive binding experiment was performed using MB as
a probe. A competitive study using MB was carried out to support the
spectral results.MB is awell-known intercalator, often used as a spectral
probe to establish themode of binding of small molecules to double-he-
lical DNA. A photosensitizer drug, methylene blue (MB), shows promis-
ing applications in biological straining and diagnosis of diseases
including carcinoma [52–54]. Intense ﬂuorescent light is emitted by
MB in the presence of DNA due to the strong intercalation between ad-
jacent DNA base pairs. Reduction of the number of binding sites on the
DNA available to MB causes quenching. Following binding with DNA,
MB ﬂuorescence decreases because of intercalation [55]. The ﬂuores-
cence spectra of DNA–MB ligand and DNA–MB complex, the mixture
of different concentrations of the compound and DNA–MB were mea-
sured using pH 7.4 Tris–HCl buffer. The emission spectra of the MB–
DNA solution upon titration with the compounds are shown in two
cases, which illustrate that MB–DNA solution emission bands slightly
decrease in intensity as the concentration of the compounds increases.
The slight decrease of the ﬂuorescence intensity is known to be due to
releasing free small MB molecules from the DNA–MB complex, de-
manding the formation of metal complex–DNA instead of intercalator
MB. A complete recovery of MBmeans the probe ﬂuorescence intensity
is sufﬁciently close to the corresponding pureMB ﬂuorescence intensity
[56]. This was not observed in our experiments (Fig. 4). Our studies de-
mand a partial replacing of MB by the two compounds from the MB–
DNA system, which is a partial intercalative mode of binding between
the title compounds and CT-DNA.
4.3. Melting of DNA Helix in Interaction with the Ligand and Copper
Complex
Denaturation of double-stranded DNA (dsDNA) is a very signiﬁcant
phenomenon involving biological, chemical and physical subsequences
[57]. The melting temperature (Tm) of DNA is deﬁned as the tempera-
ture at which 50% of double strand becomes single stranded. This has
been determined as the midpoint of the optically detected transition
curves. Moreover, the melting of DNA is an important tool for studying
the interaction of transition metal ion with nucleic acid. In addition, the
DNA melting experiment is useful in establishing the extent of interca-
lation. Thus, DNA melting temperature was determined by monitoring
Fig. 4. The emission spectra of the DNA–MB system, in the presence of: ligand (A) and Cu
complex (B), [DNA] = 2.5 × 10−5 mol L−1, [ligand] = 0–4.5 × 10−6 mol L−1, [MB] =
5 × 10−6 mol L−1, [DNA] = 2.5 × 10−5 mol L−1, [complex] = 0–5 × 10−6 mol L−1,
[MB] = 5 × 10−6 mol L−1. The arrow shows that the emission intensity changes upon
increasing complex concentration.
Fig. 5. Plots of the changes of absorbance at 260 nm of CT-DNA (7.5 × 10−6 mol L−1) on
heating in the absence and presence of the ligand and complex (3.75 × 10−6 mol L−1)
in 5 mM Tris–HCl with 50 Mm NaCl.
Fig. 6. Electronic absorption spectra of BSA (8 × 10−6 mol L−1) in the absence and
presence of different concentrations of the ligand (0–1.8 μM) (A) and complex (0–
2.5 μM) (B). The arrow shows the direction of change in absorbance upon increasing the
concentrations of the ligand and complex.
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from 25 to 100 °C both in the absence and presence of the ligand and
copper (II) complex [58]. Commonly, a ΔTm of a few degrees is consid-
ered evidence of an interaction involving groove and /or electrostatic
binding to the phosphate groups [59]. According to the literature, the in-
tercalation of natural or synthetic compounds results in the stabilization
of the DNA double helix, due to the stabilizing stacking interactions,
followed by a considerable increase in the melting temperature of
DNA [60,61]. The thermal denaturation proﬁle of CT-DNA in the absence
and presence of the ligand and complex are presented in Fig. 5. Here, the
Tm of CT-DNA was found to be 81.62 °C in buffer while, the Tm of the
DNA increased to 84.23 °C for the ligand and 85.61 °C for the Cu complex
following the addition of the ligand and Cu (II) complex. This increase
corresponds to that observed for a partial intercalative [62], suggesting
partial intercalation of the two compounds and thus supports the re-
sults obtained from the absorption and ﬂuorescence studies.
5. Protein Binding Studies
5.1. Electronic Absorption Titration
Many types of medicines and important chemical substances target
proteins. As the most abundant protein in the blood circulatory system,
serumalbumin (SA), plays important parts in the transport of drugs and
metal ions throughout the blood stream. Furthermore, proteins function
as disposers of a variety of endogenous and exogenous substances in-
cluding fatty acids and medicinal drugs [63]. Given its low cost, ready
availability and structural homology with human serum albumin
(HSA), which has a tryptophan at position 214, bovine serum albumin
is the most comprehensively studied serum albumin [64]. Thus, the ex-
amination of the interaction of potential metallo drugs with BSA is im-
portant. Binding to these proteins can provide drug transportationpaths and suggest new approaches to drug design, making it a signiﬁ-
cant ﬁeld of research in life sciences, chemistry, and clinical medicine.
A simple and pertinent method used in the investigation of structural
changes and exploration of complex formation is UV–vis absorption
measurement [65,66]. Two types of quenching mechanism, that is, dy-
namic and static quenching, can occur. Only the absorption spectra of
the excited state ﬂuorescence molecule change in dynamic quenching
mechanism. However, the change in absorption spectrum of
ﬂuorophore is induced by the formation of non-ﬂuorescence ground
state complex [67]. Absorption spectra were used to study the binding
of the ligand and Cu (II) complex with bovine serum albumin (BSA).
The absorption spectra of BSA occurred at 278 nm during the addition
of the ligand and Cu (II) complex, as observed in Fig. 6. The absorption
Fig 7. Emission spectra of BSA upon the titration of: ligand (A) and complex
(B). [BSA] = 5 × 10−6 mol L−1, [ligand] = 0–4.55 × 10−6 mol L−1, [complex] =
0–5.58 × 10−6 mol L−1. Arrow shows the change upon the increasing complex
concentration. Inset: plots of F0/FSV [ligand] and [complex] for the titration of the
complex to BSA.
40 Z. Shokohi-pour et al. / Journal of Photochemistry & Photobiology, B: Biology 162 (2016) 34–44spectrumof BSA is strongly red shifted due to the speciﬁc binding of two
compounds. This red shift and the decrease in absorption intensity indi-
cate the interaction between the ligand and Cu (II) complex with
subdomain IIA in a non-planar conformation BSA [68]. UV spectroscopy
was used to calculate the overall binding constants, as reported in [69,
70]. The ratio of the intercept to slope of the plots of 1 / (A − A0)
(where A0 is the initial absorbance of the free BSA at 278 nm, and A is
the absorbance of BSA in the presence of different concentrations of
the ligand and/or Cu (II) complex) vs. 1/[ligand] and 1/[Cu (II) complex],
which are linear lines, is used to obtain the binding constant (Kb). The
values of binding constant (Kb), were 8.6 × 104 for the ligand and
8.5 × 105 for the Cu complex, respectively. However, Kb values show
that BSA can be considered a good carrier for the transfer of these com-
pounds in vivo [71]. It is noted that the Kb of 104–106 M−1 is acceptable
for drug carriers in blood [72].
5.2. Fluorescence Quenching Studies of BSA
Fluorescence spectroscopy was used to investigate the quenching
mechanism,mode and strength of the interaction of BSAwith the ligand
and the Cu (II) complex. The strong ﬂuorescence properties of BSA are
due to the aromatic amino acids (Trp, Tyr, and Phe). The intrinsic ﬂuo-
rescence intensity of BSA, when excited at 280 nm, is mainly due to
the tryptophan residues, Trp-134 and Trp-212. On more exposure to
the environment, ﬂuorescence quenching may result from ground
state complex formation, energy transfer and dynamic quenching pro-
cesses [73]. Dynamic quenching refers to a process in which the
ﬂuorophore and the quencher come into contact during the lifetime of
the excited state, whereas static quenching refers to ﬂuorophore–
quencher complex formation when different amounts of the ligand
and the Cu (II) complex are added to a ﬁxed concentration of BSA.
Under the conditions of ﬁxed pH, temperature and ionic strength, a re-
markable decrease in the ﬂuorescence intensities of BSA was observed,
without any signiﬁcant shift in the position of the maximum emission
wavelength (Fig. 7), indicating that the interaction of the two com-
pounds with BSA could cause changes in protein secondary structure
leading to changes in trp environment of BSA [74,75]. In order to under-
stand quantitatively the quenching mechanism, the ﬂuorescence
quenching data were analyzed by the linear Stern–Volmer Eq. (3):
F0=F ¼ 1þ Ksv Q½  ¼ 1þ Kqτ0 Q½  ð3Þ
where F0 and F are the ﬂuorescence intensities of the ﬂuorophore in the
absence and presence of a quencher, respectively, Ksv is a linear Stern–
Volmer quenching constant, [Q] is the quencher concentration, kq is
the bimolecular quenching rate constant and equal to kq = Ksv / τ0
and τ0 is the average lifetime of the ﬂuorophore in the absence of the
quencher. τ0 is equal to 10–8 s for tryptophan ﬂuorescence in proteins
[76]. The plots of F0/Fsv [Q] represent a good linear relationship (Fig.
7). The KSV values, 5.6 × 104 M−1 for the ligand and 7.9 × 104 M−1 for
the Cu complex are almost coincident. It is known that a linear Stern–
Volmer plot represents a single quenching mechanism, either static or
dynamic. The obtained values of quenching constants (kq), were
2.8 × 1012 for the ligand and 3.9 × 1012 for the Cu complex, respectively.
However, the maximum scatter collision quenching constant, Kq, for
various quenchers with the biopolymer is 2 × 1010 M−1 s−1 [77].
Thus, the rate constant calculated by the protein quenching procedure
is 100-fold higher than Kq of the scatter procedure. This ﬁnding indi-
cates that a static quenching mechanism is operative [78,79].
5.3. Binding Constant and Number of Binding Sites and Gibbs Free Energy
Values
Small molecules bind independently to a set of equivalent sites on a
macromolecule. The binding constant Kb and the number of binding
sites per albumin molecule can be determined according to theScatchard Eq. (4): [80].
Log F0−Fð Þ=F½  ¼ logK þ n log Q½  ð4Þ
Kb and n values were obtained from the intercept and slope through
the double logarithm regression curve of log[(F0− F) / F] vs. log[Q]. As
shown in Fig. 8, the binding constants K and Gibbs free energy values
were (6.3 × 104 M−1, −65.4 kJ mol−1) for the ligand, and
(1.02 × 105 M−1, −68.3 kJ mol−1) for the Cu complex. In addition,
the Gibbs free energy values were obtained from Eq. (2). The negative
values ofΔG through ﬂuorescence results also supported the UV-results
of free energy changes and indicated the spontaneity of the com-
pounds–BSA binding. The plot exhibited a good linear relationship
with the linear correlation coefﬁcient of 0.994 and 0.981. The values of
Kq and Kbin for the ligand and complex suggested that the Cu complex
interacts with BSAmore strongly than the ligand. The numbers of bind-
ing stoichiometry/site (n) were approximately 0.983 for the ligand and
0.894 for the complex, which indicated that there was one binding site
for two compounds on the BSA molecular. In general, three intrinsic
proteins with intrinsic characteristics, including tryptophan, tyrosine,
and phenyl alanine residues cause the ﬂuorescence of proteins. In fact,
the intrinsic ﬂuorescence of many proteins is mostly contributed by
tryptophan alone. The emission intensity depends on the extent of ex-
posure of the two tryptophan side chains [81]. There are two tryptophan
residue intrinsic ﬂuorescence in the BSAmolecule, as reported in the lit-
erature. One of these is Trp-213 in a hydrophobic binding pocket of the
protein and the other is located on the surface of the hydrophilic region,
namely Trp134. The intrinsic ﬂuorescence of BSA is mainly due to
Trp213, because Trp134 is more exposed to a hydrophilic environment
[82]. These two compoundsmay not rapidly penetrate the hydrophobic
interior of a protein and only those tryptophan residues on the surface
of protein BSA are quenched. Therefore, it is reasonable to suspect that
Fig 8. Scatchard plots of log[(F0− F) / F] vs. log[Q] for determination of the complex–BSA
binding constant and the number of binding sites on BSA for ligand (A) and complex (B).
Fig 9. Spectral overlaps of the absorption spectra of the ligand (A) and Cu complex (B)
with the ﬂuorescence spectra of BSA. [BSA] = [ligand] = 3.0 × 10–7 mol L−1 and
[BSA] = [Cu complex] = 2.8 × 10–7 mol L−1, T = 298 K, and pH 7.4; λex = 280 nm,
λem = 285–435 nm.
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Trp213 [83].
5.4. Energy Transfer from BSA to the Ligand and Cu Complex
The overlap of the UV–vis absorption spectrum of the ligand and
complex with the ﬂuorescence emission spectrum of BSA in the wave-
length range of 285 to 440 nm [84] is shown in Fig. 9. The importance
of the energy transfer in biochemistry is that the efﬁciency of transfer
can be used to evaluate the distance between the ligand and the trypto-
phan residues in the protein. This considerable overlap forms the basis
of ﬂuorescence resonance energy transfer (FRET) [85]. The effective en-
ergy transfer from a donor to an acceptor will occur under the following
conditions: (1) production of ﬂuorescent light with a sufﬁciently long
lifetime by the donor species; (2) a signiﬁcant overlapbetween theﬂuo-
rescence spectrum of the donor and the absorption spectrum of the ac-
ceptor; and (3) the closeness of the donor species to the acceptor (the
distance of b8 nm) [86]. The energy transfer between the donor and
the acceptor is calculated using Eq. (5).
E ¼ 1−F=F0 ¼ R06= R06 þ r6
  ð5Þ
where r is the donor–acceptor distance, F and F0 are the ﬂuorescence
intensities of BSA in the presence and absence of a quencher and R0 is
the critical distance when the transfer efﬁciency is 50%, which can be
calculated based on Eq. (6) [87].
R06 ¼ 8:8 10−25K2N−4ΦJ ð6Þ
In the above equation, K2 is the spatial orientation factor of the di-
pole, N is the refractive index of the medium, Φ is the ﬂuorescence
quantum yield of the donor, and J is the overlap integral of theﬂuorescence spectrum of the donor with the absorption spectrum of
the acceptor (Fig. 9). The value of J is calculated using Eq. (7): [88].
J ¼ ΣF λð ÞƐ λð Þλ4Δλ
h i
= ΣF λð ÞΔλ
  ð7Þ
where F(λ) is the ﬂuorescence intensity of BSA in the absence of a
quencher at wavelength λ and Ɛ(λ) is the molar extinction coefﬁcient
of the acceptor at λ. In the present case, K2 = 2/3, N = 1.336 and
Φ= 0.15. Hence, using Eqs. (5)–(7) above, the following parameter
can be calculated: J = 1.24 × 10−14cm3 L mol−1, R0 = 2.64 nm, E =
0.361 and r=2.45 nm for the ligand and J=1.08× 10−14 cm3 Lmol−1,
R0=2.58nm, E=0.148 and r=3.46nm for theCu complex. Obviously,
the distance between two compounds and BSA is b8 nm, and
0.5R0 b r b 1.5R0, implying that the energy transfer from BSA to two
compounds occurred with high probability. The bigger r value com-
pared with R0 again indicates the presence of a static quenching mech-
anism in the binding of the two complexes to BSA [89].
6. Cytotoxicity Assay
In vitro cytotoxicity of compounds was evaluated by means of the
standard MTT-dye reduction assay, which is a broadly used method in
biological evaluation. Recently, new metal complexes were assessed
using this method [90,91]. MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-tetrazolium bromide] colorimetric assay was used to evaluate
the cytotoxic activity of the ligand and Cu complex. This test is based on
themetabolic reduction of soluble MTT bymitochondrial enzyme activ-
ity of viable tumor cells. The product is an insoluble colored formazan,
which can be quantiﬁed spectrophotometrically after dissolution in
dimethylsulfoxide (DMSO). In order to perform the cytotoxicity assay,
200 μl of cells (5 × 104 cells ml−1) was seeded in 96 well micro plates
and incubated for 24 h (37 °C, 5% CO2 air humidiﬁed). Subsequently,
20 μl of prepared concentrations of each compound was added to the
wells. The compounds were dissolved in DMSO before being added to
the culture media. Control groups contained DMSO at the same
Fig 10.Dose-dependent cytotoxic activity of the ligand and Cu complex against JURKAT (A), SKOV3 (B), andU87 (C) cancer cell lines and thenormal PBMC cell line (D) at concentrations of
10 and 100 μM. Results are the mean ± SD of three independent experiments. All data are signiﬁcant differences from untreated control by p b 0.05.
Table 4
Selective cytotoxicity of ligand and Cu complex against 3 different cancer cell lines.
Cell line Compound IC50 SI
JURKAT Cu complex 21.27 14
Ligand 60.82 5
SKOV3 Cu complex 64.98 4.6
Ligand 87.9 3.5
U87 Cu complex 28.4 10.5
Ligand 48.35 6.2
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20 μl of MTT solution (5 mg ml−1 in phosphate buffer solution) was
added and the plates were incubated for another 3 h. 150 μl of the me-
dium containing MTTwere then gently replaced by DMSO and pipetted
to dissolve any formazan crystal formed. Absorbance was then deter-
mined at 560 nm using an ELISA plate reader (Awareness Technology
Inc., stat fax 2100). Results were generated from three independent ex-
periments and each experiment was performed in triplicate. IC50 (con-
centration which inhibits cell growth by 50%) values of ligand and Cu
complex against each tested cell linewas calculated using non-linear re-
gression of concentration-response curves. The selectivity index (SI)
was also calculated based on the IC50 ratio of normal human peripheral
blood mononuclear cells (PBMCs) and cancer (JURKAT, SKOV3 and
U87) cells. SI value indicates selectivity of the sample to the cell lines
tested. Samples with SI values N2 were considered to have a high selec-
tivity [92].
6.1. Selective Cancer-cell Cytotoxic Activity
The ligand and Cu complex were tested for cytotoxicity against 3
human cancer cell lines. Both compounds showed low toxicity
(IC50 N 300 μM) against normal peripheral blood mononuclear cells
(PBMCs), but demonstrated a high selective cytotoxicity against 3
human cancer cell lines. The ligand showed cytotoxicity against JURKAT,
SKOV3, and U87 cancer cell lines with IC50 values of 60.82, 87.9 and
48.35 μM, respectively. Notably, the Cu complex exerted highercytotoxicity against JURKAT, SKOV3, and U87 cancer cell lines with
IC50 values of 21.27, 64.98 and 28.4 μM, respectively (Fig. 10 and Table
4).
As depicted in Fig. 10, both compounds exhibited signiﬁcant dose-
dependent inhibition on proliferation and viability of different cancer
cells. Selectivity of the cytotoxic activity was determined by comparing
the cytotoxic activity (IC50) of the compound against each cancer cell
with that of the normal cell line PBMC (Table 4).
7. Conclusions
We have synthesized a novel Schiff base derived from the
gabapentin drug and copper (II) complex containing ligand. The struc-
ture of the ligand was characterized by X-ray crystallography and the
copper (II) complex was characterized by FT-IR, ESI-MASS and other
methods. The binding interaction of two biologically relevant
43Z. Shokohi-pour et al. / Journal of Photochemistry & Photobiology, B: Biology 162 (2016) 34–44compounds with calf thymus DNA, bioactivity investigation by UV–vis
and ﬂuorescence spectroscopy, and other spectroscopic measurements
unambiguously suggested the binding of a partial intercalative by the
probe with the DNA. The reactivity towards BSA revealed that the
quenching of BSA ﬂuorescence by two compounds was of the static
type. The cytotoxic studies show that the two compounds exhibit high
selective and dose-dependent cytotoxic activity against three different
cancer cell lines. In addition, the results of cytotoxicity revealed that
the Cu complex is more effective than its free ligand under identical ex-
perimental conditions. It is interesting that theDNAand protein binding
abilities of the two compounds are consistent with in vitro cytotoxic ac-
tivity and follow the order of Cu complex N ligand.
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